This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

CHARM trial programme

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The CHARM trial programme asked the question: should angiotensin receptor antagonists be given to patients with heart failure who are already taking angiotensin-converting enzyme inhibitors (ACE inhibitors)?

There were three individual trials:

  1. CHARM-Alternative - effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors
  2. CHARM-Added - effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors
  3. CHARM-Preserved - effects of candesartain in patients with chronic heart failure and preserved left-ventricular ejection fraction

These trials showed that, in patients with chronic heart failure, the angiotensin receptor blocker candesartan led to a reduction in mortality (especially cardiovascular) and hospital admissions for worsening chronic heart failure. The most benefit was seen in patient with reduced left ventricular ejection fraction with or without baseline angiotensin converting enzyme inhibitor treatment.


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.